Drugs / FE 201836
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03201419 | Jul 2017 → Oct 2019 | — | Ferring Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FE 201836 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03201419 ↗ |
| Route | Oral | “FE 201836 500 μg oral solution and placebo orally disintegrating tablet (ODT), administered once daily” NCT03201419 ↗ |